TORONTO, Sept. 6, 2018 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical
company specializing in central nervous system ("CNS") and
cardiovascular markets, announces that it has appointed Mr.
Tim Hendrickson, the Company's Vice
President, Finance & Administration, to the role of Chief
Financial Officer ("CFO"), effective immediately.
"Tim was one of the first employees hired after HLS was founded
in 2015, and he has been a valuable member of our leadership team
as we have transitioned from a start-up to a publicly-traded
company in a short period of time," said Greg Gubitz, CEO of HLS. "Prior to HLS, Tim
worked at several publicly-traded companies in the pharmaceutical
industry, and we'll look to draw on his experience and expertise as
we expand our product portfolio, manage our operational growth and
establish ourselves as one of Canada's leading specialty pharmaceutical
companies."
Mr. Hendrickson joined HLS in 2015 as Vice President, Finance
& Administration. Prior to that, he was Senior Director,
Finance, at Cubist Pharmaceuticals Canada, Inc., a specialty
pharmaceutical company whose parent company was publicly-traded on
NASDAQ and was acquired in 2015. From 2009 – 2014, he was Director,
Finance and Business Development, at Warner Chilcott Canada Co., a
mid-sized specialty pharmaceutical company whose parent company was
also publicly-traded on NASDAQ and was acquired in 2013. From 2003
– 2009, Mr. Hendrickson was Canada Finance Leader at Procter &
Gamble Pharmaceuticals Canada Inc., and prior to that, he held a
series of progressive financial and leadership roles at Procter
& Gamble, Inc. from 1998 – 2003. Mr. Hendrickson has a Bachelor
of Commerce degree from the University of
Toronto and an MBA from the Rotman School of Management,
University of Toronto.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company
focused on the acquisition and commercialization of late stage
development, commercial stage promoted and established branded
pharmaceutical products in the North American markets. HLS's focus
is on products targeting the central nervous system and
cardiovascular therapeutic areas. HLS's management team is composed
of seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE HLS Therapeutics Inc.